# Radio-antibody & radio-ADC

Source: https://nuclide.cc/technologies/radioimmunotherapy/  
Nuclide record `radioimmunotherapy` (Technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.

## Summary

90Y-ibritumomab (Zevalin) and 131I-tositumomab proved the concept in lymphoma but were commercially abandoned. Renewed interest: 225Ac-labelled antibodies to PSMA (J591), CD33 (lintuzumab), DLL3, HER2, and 177Lu-labelled antibodies. Long antibody half-life is both a dosimetry advantage and a marrow-toxicity problem; pretargeting and fragment approaches address it.

## Fields

- Kind: Technology
- Status: phase-2
- Last checked: 2026-09-04
- Tags: frontier
- Principle: A chelator-conjugated antibody or fragment carries 177Lu, 225Ac, 212Pb, or 131I.
- Strengths: Any ADC target becomes a radiation target; Bystander crossfire independent of payload chemistry
- Limitations: Marrow dose from circulating antibody; Manufacturing complexity

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Radioimmunotherapy
- Wikipedia: https://en.wikipedia.org/wiki/Radioimmunotherapy

## Connected records

- ideas: [Alpha radioligands after ADC failure](https://nuclide.cc/ideas/idea-alpha-after-adc/), [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://nuclide.cc/ideas/idea-caix-theranostics/), [Pretargeted alpha radioimmunotherapy](https://nuclide.cc/ideas/idea-pretargeted-alpha-therapy/)
- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Iodine-131](https://nuclide.cc/isotopes/i-131/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- technologies: [Auger-electron therapy](https://nuclide.cc/technologies/auger-electron-therapy/), [Pretargeted radioimmunotherapy](https://nuclide.cc/technologies/pretargeted-radioimmunotherapy/), [Sarcophagine chelation](https://nuclide.cc/technologies/sarcophagine-chelation/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://nuclide.cc/technologies/therapy-isotope-supply-chain/)
- targets: [DLL3](https://nuclide.cc/targets/dll3/), [HER2](https://nuclide.cc/targets/her2/), [PSMA](https://nuclide.cc/targets/psma/), [Sortilin (SORT1)](https://nuclide.cc/targets/sortilin/)
- companies: [Abdera Therapeutics](https://nuclide.cc/companies/abdera-therapeutics/), [Actinium Pharmaceuticals](https://nuclide.cc/companies/actinium-pharmaceuticals/), [Convergent Therapeutics](https://nuclide.cc/companies/convergent-therapeutics/)
- journals: [Cancer biotherapy & radiopharmaceuticals](https://nuclide.cc/journals/cancer-biotherapy-and-radiopharmaceuticals/)
- indications: [Follicular lymphoma](https://nuclide.cc/indications/follicular-lymphoma/), [Renal cell carcinoma](https://nuclide.cc/indications/rcc/)
- drugs: [Ibritumomab tiuxetan](https://nuclide.cc/drugs/ibritumomab-tiuxetan/), [Iodine-131 tositumomab](https://nuclide.cc/drugs/i-131-tositumomab/), [Iomab-B](https://nuclide.cc/drugs/iomab-b/), [Lutetium-177 rosopatamab tetraxetan](https://nuclide.cc/drugs/tlx-591/)
- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/)
- pairings: [Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)](https://nuclide.cc/pairings/rituximab-then-ibritumomab-tiuxetan/)

---
JSON: https://nuclide.cc/api/v1/entities/radioimmunotherapy.json